Treatment of Ménétrier's Disease with a Monoclonal Antibody against the Epidermal Growth Factor Receptor.

The article presents information related to the treatment of MÉnÉtrier's disease or hypoproteinemic hypertrophic gastropathy. This disease is characterized by giant hypertrophic folds that most often involve the fundus, excess mucus secretion, decreased acid secretion, hypochlorhydria, and hypoproteinemia due to selective loss of serum proteins across the gastric mucosa. Increased signaling of the epidermal growth factor receptor has been implicated in the pathogenesis of MÉnÉtrier's disease. There is no known association between primary pulmonary hypertension and MÉnÉtrier's disease. The long-term side effects of epoprostenol, which include nausea and vomiting, are dose-dependent and resolve with dose reduction.